MedTrace Logo

Acitretin or Tazarotene Gel and Excimer Laser for Treatment of Psoriasis

NCT01094717 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2019-06-26

Study results available
· View outcomes & findings →

Summary

This is a randomized, double-blind study of excimer (308-nm UVB) laser added to either tazarotene 0.1% gel or acitretin 25 mg daily for plaque psoriasis.

The primary objective of this study is to compare the improvement of psoriatic plaques with and without excimer laser (308-nm UVB) treatment, applied in a randomized and blinded fashion, in subjects on acitretin 25 mg or tazarotene gel 0.1% QD.

Conditions

Interventions

DRUG

Acitretin 25Mg Oral Capsule

Acitretin 25 mg oral daily for 12 weeks

DEVICE

Excimer laser

Lesions on randomly assigned left or right side of body were treated with 308nm excimer laser.

DRUG

Tazarotene 0.1% Gel,Top

Topical tazarotene 0.1% gel was applied daily to active lesions.

DEVICE

Sham excimer laser

Lesions on randomly assigned left or right side of body were treated with sham excimer laser (opaque cover on the laser device).

Sponsors & Collaborators

Principal Investigators

  • Kristina C Duffin, MD · University of Utah

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2011-09-30
Completion
2011-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01094717 on ClinicalTrials.gov